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ABSTRACT
Background: Transcatheter aortic valve implantation (TAVI) is 
a new modality of treatment especially dedicated to patients 
with high surgical risk. In these patients, TAVI increased sur-
vival and improved quality of life when compared to standard 
treatment (drug therapy with or without percutaneous aortic 
balloon valvuloplasty). Our objective was to perform a cost-
efficacy analysis of the implementation of TAVI in the Brazilian 
Supplemental Health System. Methods: We developed a predic-
tive model to assess the cost-effectiveness of the procedure in 
the long-term, and a Weibull regression analysis with a time 
horizon of 5 and 10 years, to estimate survival data for over 
24 months. In addition, a deterministic sequential Markov 
model was developed. Results were expressed as incremen-
tal cost-effectiveness ratio (ICER) per years of life saved and 
progression-free years of life. Results: In a standard scenario, 
where the cost of TAVI was estimated as R$ 65 millions, the 
ICER value (cost/year of life saved) in 5 years was R$ 72,520.65. 
When the time horizon was adjusted for 10 years, this amount 
decreased to R$ 41,653.01. Conclusions: The model indicated 
that TAVI has superior effectiveness and higher incremental 
cost. Furthermore, the incorporation of TAVI in the List of 
Health Procedures and Events of the Brazilian Supplemental 
1 Doctorate Student. Technician Director of the Hemodynamics and 
Interventional Cardiology Service (Cardiocenter) of Hospital Unimed 
João Pessoa. João Pessoa, PB, Brazil.
2 Pharmaceutical. Pharmacoeconomist at Evidências – Credibilidade 
Científica. Campinas, SP, Brazil.
3 Oncologist Physician. Consultant of Assessments of Technology 
in Health at Evidências – Credibilidade Científica. Campinas, SP, 
Brazil.
4 Full professor. Director of the Hemodynamic and Interventional 
Cardiology Service at Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo. São Paulo, SP, Brazil.
5 Doctor. Medical Coordinator of Interventional Cardiology at Hospital 
Israelita Albert Einstein. São Paulo, SP, Brazil.
6 Doctor. Technician Director of the Hemodynamics and Interventional 
Cardiology Laboratory at Instituto de Cardiologia do Rio Grande do 
Sul. Porto Alegre, RS, Brazil.
7 Jornalist. MsC at Evidências – Credibilidade Científica. Campinas, 
SP, Brazil.
8 Doctor. Oncologist Physician. Director of Evidências – Credibilidade 
Científica. Campinas, SP, Brazil.
9 Full professor. Director of the Hemodynamics and Interventional 
Cardiology Unit of Hospital das Clínicas da Faculdade de Medicina de 
Ribeirão Preto da Universidade de São Paulo. Ribeirão Preto, SP, Brazil.
10 Full professor. Director of the Center of Interventions in Heart 
Structural Diseases of Instituto Dante Pazzanese de Cardiologia. São 
Paulo, SP, Brazil.
Correspondence to: Marcelo A. C. Q. Lopes. Av. Max Zagel, 91 – 
Camboinha – Cabedelo, PB, Brazil – CEP 58310-000
E-mail: mqueiroga@terra.com.br
Received on: 6/1/2013 • Accepted on: 8/6/ 2013
Original Article
RESUMO
Implante por Cateter de Bioprótese Valvular Aórtica 
para Tratamento de Estenose Valvar Aórtica Grave 
em Pacientes Inoperáveis sob Perspectiva da Saúde 
Suplementar – Análise de Custo-Efetividade
Introdução: O implante por cateter de bioprótese valvular 
aórtica (TAVI, do inglês transcatheter aortic valve implantation) 
constitui nova modalidade de tratamento destinada, sobretudo, 
aos pacientes com elevado risco cirúrgico. Para esses pacientes, 
o TAVI resultou em aumento da sobrevivência e melhora da 
qualidade de vida, comparativamente ao tratamento padrão 
(medicamentoso, com ou sem valvuloplastia aórtica percutânea). 
Nosso objetivo foi realizar análise de custo-efetividade da 
implementação do TAVI no Sistema de Saúde Suplementar 
brasileiro. Métodos: Foram desenvolvidos um modelo preditivo, 
para avaliar custo-efetividade real do procedimento em longo 
prazo, e uma regressão de Weibull com tempo horizonte de 
5 e 10 anos, para estimar dados de sobrevida por mais de 24 
meses. Adicionalmente, foi desenvolvido modelo de Markov 
sequencial e determinístico. Resultados foram expressos como 
razão de custo-efetividade incremental (RCEI) por anos de vida 
ganhos e anos de vida livres de progressão. Resultados: Para o 
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Health System would have an incremental budgetary impact 
over the next 5 years, ranging from R$ 70 millions to R$ 
121 millions, consistent with other technologies which have 
already been incorporated by the system.
 
 
 
 
 
 
 
 
DESCRIPTORS: Aortic valve stenosis. Heart valve prosthesis 
implantation. Bioprosthesis. Catheters. Supplemental Health. 
Cost-benefit analysis.
is to restore aortic valve function through minimally 
invasive techniques, thus avoiding general anesthesia 
and surgical procedures, such as median sternotomy, 
aortic clamping, and cardiopulmonary bypass.13,14 In 
Brazil, TAVI was introduced in 2008, and since then 
has been performed in different private hospitals in 
various regions of the country. Currently, approximately 
700 such procedures have been performed in Brazil.
Several international organizations recommend 
and approve the use of TAVI for AS in inoperable 
patients, such as the National Institute for Health and 
Clinical Excellence (NICE) of Great Britain,15 Ontario 
Health Quality,12 and the National Health Committee 
of New Zealand.16 In Brazil, both Brazilian So ciety 
of Hemodynamics and Interventional Cardiology (So-
ciedade Brasileira de Hemodinâmica e Cardiologia 
Intervencionista [SBHCI])6 and Brazilian Society of 
Cardiology (Sociedade Brasileira de Cardiologia [SBC])11 
recommend TAVI for the group of patients considered 
inoperable. However, this important technique has 
not yet been incorporated in the list of healthcare 
practices in Brazil.
The present study aimed to perform an economic 
analysis of the impact of the incorporation of TAVI 
originally intended for patients with AS in the Brazilian 
private healthcare system, assessing its cost-effectiveness 
in patients not eligible for surgical treatment and de-
termining its budgetary impact.
METHODS
The current evidence related to the effectiveness 
of TAVI in the treatment of patients with severe AS is 
restricted to a short period. A predictive model was 
developed in order to analyze, in the long run, the 
cost-effectiveness of this therapeutic modality, aiming 
to assess its real benefits, as well as the incremental 
costs of implementing this treatment. The effectiveness 
cenário padrão, no qual o custo da TAVI foi estipulado em R$ 
65 mil, o valor da RCEI (custo/ano de vida salvo) em 5 anos 
foi de R$ 72.520,65. Alterando-se o tempo horizonte para 10 
anos, esse valor diminuiu para R$ 41.653,01. Conclusões: O 
modelo apontou que o TAVI apresenta efetividade superior e 
maior custo incremental. Além disso, a incorporação do TAVI 
no Rol de Procedimentos e Eventos em Saúde da Agência Na-
cional de Saúde Suplementar acarretaria impacto orçamentário 
incremental nos próximos 5 anos, variando de R$ 70 milhões 
a R$ 121 milhões, compatível com o de outras tecnologias já 
incorporadas no âmbito da Saúde Suplementar.
 
 
DESCRITORES: Estenose da valva aórtica. Implante de prótese 
de valva cardíaca. Bioprótese. Cateteres. Saúde Suplementar. 
Análise custo-benefício.
A ortic stenosis (AS) is now the most common val-vulopathy among the elderly, with an estimated prevalence of up to 5% in individuals over 75 
years of age. The current relative ageing of the global 
population further increases the social importance of 
this pathology, with significant impact on public health 
policies.1,2
Typically, after a long period of clinical latency, 
symptoms of angina, syncope, and heart failure arise. 
Survival after the onset of symptoms without valve re-
placement surgery is low: 60% at one year and 32% 
at five years,3,4 with high risk of sudden death.5
The standard treatment for this condition is surgical 
valve replacement, which in observational trials proved 
able to increase survival and improve symptoms com-
pared to data from historical cohorts of patients treated 
without surgery.5-7 The surgical procedure is considered 
safe, with average complication rates of approximately 
4% to 5%, which may be less than 1% in patients aged 
below 70 years.8
However, a substantial subgroup has high surgical 
risk, both due to advanced age and association with 
comorbidities, making them ineligible for surgery. The 
rates of ineligibility are approximately 30% to 40% 
of patients.9,10 In Brazil, there are no published data 
evaluating these statistics. For this group of patients 
with no prospect of surgical treatment, the treatment 
consists of clinical and medical support, and of percu-
taneous balloon aortic valvuloplasty. Such therapeutic 
resources, even in association, have limited effectiveness 
and are not able to improve survival of patients.3,6,11 
The prognosis is ominous, with mortality at one, two, 
and three years of 45%, 65%, and 77%, respectively.12
The implant of aortic valve bioprosthesis by catheter 
(transcatheter aortic valve implantation [TAVI]) is a new 
technique that has been successfully introduced for the 
treatment of patients deemed inoperable. Its main objective 
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data were taken from the only randomized prospective 
clinical trial published: the PARTNER cohort B trial.17
Target population 
Patients affected by severe and symptomatic AS, 
without surgical perspective. 
Time horizon
A time horizon of 60 months (five years) was con-
sidered to be more appropriate to capture patient’s cost 
and clinical benefit data, since data on longer periods 
are scarce and a model for extrapolating these data 
could cause excessive bias in the results. 
Perspective
The analysis was conducted under the perspective 
of the Brazilian private healthcare system, and only 
direct costs were considered. Indirect costs, such as 
loss of productivity due to illness, were not included. 
Weibull regression
In order to estimate survival data for more than 
24 months, a Weibull regression with time horizon of 
five and ten years was developed. From the results of 
the PARTNER trial,17 survival data of patients in both 
treatment modalities, at three months intervals, were 
collected. These data were used to develop the survival 
curve designed with the use of Weibull regression, 
obtaining estimates of survival data up to ten years 
(Figure 1).
Markov model 
In addition, this model uses short-term data avail-
able, and relies on them in order to predict the costs 
by increasing the life expectancy and health benefits 
associated with different treatment options. Thus, a 
deterministic sequential Markov model was developed 
with an optional random element. From survival data 
of the patients obtained in the PARTNER trial,17 and 
from the corresponding estimated survival over the 
remaining years through the Weibull regression, the 
model structure considered two health states: survival 
and death (Figure 2).
As the survival data obtained from the PARTNER 
study were based on observation of deaths from all 
causes, it was decided to construct a simple model 
(two states of health). To do so, all costs and likeli-
hoods of comorbidities (stroke; serious complications, 
such as kidney failure and implantation of artificial 
heart pacemaker; and medical visits and hospitaliza-
tions) were considered. Each cycle was estimated on 
a time horizon of three months and, for each cycle, 
the chances of mortality were changed over time, in 
accordance with data from the PARTNER trial and the 
Weibull projection.
The model parameters include the mean durations 
in which the patient remains in each state of health, as 
well as the costs associated with such conditions. The 
model was structured in a Microsoft Excel database. 
This database used quarterly cycles with probabilities for 
the possibility of a change in the patient health status 
during each period. All consequences were reported 
according to the expected cost and to the results on 
the health status of each patient.
In the model, the planning horizon used was the 
patient’s lifetime. Therefore, the results on the health 
status and the costs occurring in the future have less 
weight than the present results. Thereby, discounts of 
the global results on health status and respective costs 
were applied. The guidelines by the Brazilian Ministry 
of Health recommend a discount of 5% for costs and 
benefits. 
Costs
Only direct medical costs, such as medications, 
procedures, and hospitalization, collected under the 
perspective of Brazilian private healthcare system 
for the year 2013, were considered. The considered 
expenditure of resources was based on data from a 
pre-planned economic study, conducted in parallel with 
Figure 1 – Weibull regression for data of survival designed for ten 
years in standard treatment groups (ST) and with transcatheter aortic 
valve implantation (TAVI), from PARTNER trial data.17 Figure 2 – Markow model structure.
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the PARTNER B cohort trial,18 and the drug treatment 
standard was based on a registry that included high-risk 
patients with severe and symptomatic AS.19
Although in the PARTNER study 83.8% of control 
patients underwent percutaneous balloon aortic val-
vuloplasty, this percentage was not considered gener-
ally applicable to the therapeutic scenario observed 
in Brazil, where, according to the Brazilian Unified 
Health System database (Banco de Dados do Sistema 
Único de Saúde – DATASUS), only 121 percutaneous 
balloon aortic valvuloplasties were performed in 2011. 
Through a panel of experts appointed by the SBHCI,6 
it was estimated that only 30% of the control group 
population would perform this procedure (this parameter 
varied in the sensitivity analysis).
Since the use of percutaneous balloon aortic val-
vuloplasty does not alter the survival of adult patients 
with unresectable symptomatic severe AS,3,10 it was 
considered that the effectiveness data from the PART-
NER trial still prevailed, even estimating a lower use 
of that procedure in Brazilian population covered by 
this economic study.
Taking into account the perspective adopted in the 
analysis and aiming to establish the monthly pharma-
ceutical costs of the disease, the mean values of drug 
purchase were not considered, since, typically, healthcare 
plans do not reimburse patients for the drugs used in 
the standard treatment arm (amiodarone, digoxin, and 
furosemide). Thus, the patient must afford these expenses.
Based on market data, the cost of the prosthesis 
used for TAVI was estimated at R$ 65,000.000 and the 
medical procedure was estimated at R$ 23,518.42, 
obtained from a micro-costing data analysis, an 
evaluation technique that involves gathering detailed 
data about resources used and the value of these re-
sources. The costs arising from events resulting from 
the treatment of patients with severe AS in this model 
were obtained from an expert panel for the collec-
tion of use of resources, consulting sources related 
tothe private healthcare system, such as Brazilian 
Hierarchical Classification of Medical Procedures 
(Classificação Brasileira Hierarquizada de Procedi-
mentos Médicos – CBHPM), 5th edition; Chamber of 
Drug Market Regulation (Câmara de Regulação do 
Mercado de Medicamentos – CMED); and Simpro; 
among others (Table 1).
Incremental cost-effectiveness ratio
The additional cost per extra unit of benefit obtained, 
known as incremental (or marginal) analysis, and its 
results are presented as incremental cost-effectiveness 
ratios (ICERs). The models were used to estimate out-
comes (life-years gained) and costs to guide patients 
on their decision regarding each treatment alternative. 
ICERs were calculated as follows:
ICER =
Treatment cost – Alternative cost
Treatment effect – Alternative effec
Where: ICER, incremental cost-effectiveness ratio; cost, 
costs (in R$); effect, effectiveness (in years of life gained). 
Sensitivity analysis
A univariate sensitivity analysis was performed on 
the two main variables of the model: the time-horizon 
of this cost-effectiveness analysis and the cost of incor-
poration of the prosthesis. 
Given that the distributions were adjusted to the 
fundamental parameters in the model, each patient 
among the 5,000 included in the analysis showed a 
different trajectory of the disease and, thus, varied results 
and costs. Therefore, an additional probabilistic analysis 
was also conducted in order to further evaluate the 
variability of the results, and the conclusion regarding 
the possibility that a given intervention would present 
cost-effectiveness. All distributions in the model were 
independently tested.
All costs of treatment (drug, procedures with a 
balloon catheter, and TAVI) were varied by ± 20% 
using gamma variation, as well as hospitalization and 
medical consultations costs. The rates of pacemaker 
implantation, stroke, serious complications, and num-
ber of hospitalizations and clinical visits were varied 
by ± 25%. The analyzed treatment effectiveness data 
were varied by ± 10%. According to the guidelines of 
the Ministry of Health, the discount rate was varied 
between 0% and 10%.
RESULTS
By employing TAVI in the treatment of inoperable 
patients with severe AS, the estimated total cost of 
treatment, over five years, was R$ 123,019.76. This 
value included: costs of the procedure, valve pros-
thesis, consultations with specialists, hospitalization 
expenses, and costs of adverse events. The cost of the 
standard treatment (pharmacological) was estimated at 
R$ 35,815.12, with the addition of costs of specialists 
TABLE 1  
Events’ cost
Procedure Cost (R$)
Renal failure (dialysis) 68.493,35
Implantation of pacemaker 13.203,26
Stroke 4.722,08
Severe vascular complications 6.001,15
Hospitalizations (other causes) 1.503,25
Medical appointments 63,00
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and hospitalizations, among others. The values  were 
obtained from a micro-costing study in order to assess 
the total cost of the procedure, considering the tables 
currently used by the operators of healthcare plans.
Patients treated with TAVI had longer life expectancy 
compared to patients who underwent only conservative 
therapy. In five years of analysis, the mean survival 
in the group treated with TAVI was 2.5 years. In the 
group that received only standard treatment, the mean 
survival was 1.53 years.
For the standard scenario, in which the cost of TAVI 
was set at R$ 65,000, the value of the ICER (cost/year 
of life saved) at five years was R$ 90,161.29. However, 
when changing the time horizon to the years, the value 
of ICER decreased to R$ 55,130.84.
Additionally, the value of the valve prosthesis was 
altered, between R$ 30,000 and R$ 65,000 (baseline 
case value). The results of the ICER of this five-year 
time horizon analysis, with this variance in the cost 
of the valve prosthesis, ranged between R$ 49,770.00 
and R$ 85,957.00. The values  for each change are 
described in Figure 3. 
An additional probabilistic analysis was also per-
formed, whose results were evaluated and classified 
as follows: quadrant 1 (incremental effectiveness  >  0 
and incremental cost  > 0); quadrant 2 (incremental 
effectiveness <  0 and incremental cost  >  0); quadrant 
3 (incremental effectiveness <  0 and incremental cost 
< 0), and quadrant 4 (incremental effectiveness > 0 and 
incremental cost <  0).
It was observed that most of the simulations had 
their results in quadrant 1 (99.9%), i.e., in the simulation, 
almost all patients using TAVI, compared to standard 
treatment, were characterized by greater efficiency and 
also by an incremental cost, showing the robustness of 
the analysis model.
In addition, an analysis of budgetary impact (using 
Budget Impact Models [BIM]) was developed, in order 
to simulate the financial impact of the introduction of 
TAVI in the private healthcare system. This analysis was 
performed by comparing the cost of the first years of 
treatment of inoperable patients with severe AS. Thus, 
the budgetary impact of this new technology compared 
the cost of acquisition of the valve bioprosthesis (for 
this group of patients) with the other current treatment 
option.
The model was created in Microsoft Excel database, 
in accordance with the guidelines of budgetary impact 
analyses published in 2007 by International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR). 
This model estimates the budgetary impact by combin-
ing epidemiological data, hypotheses of evolution of 
the use of various therapies available (treatment flow), 
resources used, and costs of pharmacological treatment 
and of adverse events associated, comparing two or 
more different scenarios.
For the hypothetical scenarios envisioned (baseline 
and alternative scenarios), the market profile for the new 
technique (TAVI) over five years was estimated from the 
projected trend of use, since there are no real-world 
data for these scenarios. In the baseline scenario, the 
initial premise was that the transcatheter aortic valve 
implantation should have a usage profile derived of the 
opinion of the expert panel already nominated. As a 
sensitivity analysis, an extra scenario was considered 
(named “alternative scenario”), in which a higher usage 
profile of TAVI after the incorporation of the new tech-
nology was estimated (Figure 4).
For each year of the five-year horizon of the 
model, it was assumed, in the present scenario, that 
all eligible patients should be fully treated with the 
current standard therapy (drugs and balloon catheter 
dilation). 
The budgetary impact analysis demonstrated that, 
in the current scenario, the estimate of total expen-
ditures over the time horizon of five years would 
be approximately R$ 56.9 million. Both hypothetical 
Figure 3 – Probabilistic cost-effectiveness plan.
Figure 4 – Penetration rate of transcatheter aortic valve implantation 
(TAVI) compared to the number of eligible patients for the procedure.
Baseline scenario
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Current therapeutic standard 70% 65% 60% 55% 50%
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Current therapeutic standard 50% 40% 30% 20% 10%
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(baseline and alternative) scenarios showed increases 
in budgetary impact. In the baseline scenario, in which 
the distribution of TAVI values was obtained from the 
expert panel, the budgetary impact was R$ 127 million 
over five years (Figure 5).
Figure 6 depicts the incremental budgetary impacts 
overfive years in the private healthcare system in each 
hypothetical scenario (TAVI incorporation) compared 
to the current scenario (without TAVI incorporation).
In both hypothetical scenarios, the budgetary 
impact is due primarily to the cost of the valve 
prosthesis for transcatheter implantation, accounting 
for approximately 43% of total costs in the baseline 
scenario, when compared to other costs analyzed in 
the model (hospitalization and medication expenses, 
among others). In the alternative scenario, the valve 
prosthesis was responsible for approximately 55% 
of the costs, since its market distribution would be 
higher in that scenario.
DISCUSSION
Since 1998, with the regulation of private healthcare 
in Brazil and the creation of the Brazilian National 
Regulatory Agency for Private Health Insurance and 
Plans (Agência Nacional de Saúde Suplementar – ANS), 
there has been sustained growth in this sector, involv-
ing operators of healthcare plans, beneficiaries, and 
service providers. Currently, over 48 million Brazil-
ians use the private healthcare system. According to 
data from the Descriptive Document of ANS, over R$ 
68 billion were spent by healthcare plan operators in 
2012. Due to legal requirements, ANS assumed the 
task of upgrading, every two years, the List of Health 
Procedures and Events, a reference guide for minimum 
mandatory coverage. In this context, the need to as-
sess the incorporation of new medical technologies is 
included; besides, an economic analysis is of major 
importance for the inclusion of new procedures in the 
list of mandatory coverage.
For Norman Daniels,20 the decisions on the al-
location of financial resources in health consist of 
determining what kind of health services will exist in 
a society, who will receive them and on what basis, 
and who will provide these services; also, how their 
funding will be distrubuted, and how the power and 
control of these services will be distributed. In Brazil, 
this decision is of the responsibility of the Ministry of 
Health. Regarding the incorporation of new technolo-
gies, since 2012 this task has been the responsibility of 
the National Commission on Technology Incorporation 
(Comissão Nacional de Incorporação de Tecnologias, 
CONITEC), whose decisions are taken based on the 
relevance and impact of the implementation of technol-
ogy in the health system, as well as the existence of 
scientific evidence of efficacy, accuracy, effectiveness, 
safety, and economic feasibility studies on the proposed 
technology, compared to other previously incorporated 
technologies.
In the sphere of private healthcare, even before the 
creation of CONITEC, the ANS already had, by legal 
determination, the power to update the list of manda-
tory coverage of medical procedures and, therefore, to 
determine the incorporation of medical technologies in 
its area of responsibility. 
It should also be emphasized that, in the face of 
the population aging process, the treatment in ques-
tion has the potential to benefit a significant portion 
of Brazilian society. According to ANS, approximately 
2.5 million beneficiaries are over 70 years-old. Based 
on the estimated prevalence of 5% of this population 
with severe AS, certainly a considerable fraction may 
be considered as without the prospect of undergoing 
surgery for correction of the disease and, thus, its mem-
bers will be candidates for TAVI. In Brazil, it must be 
emphasized that the Statute of the Elderly determines 
Figure 6 – Impact after the incorporation of the transcatheter aortic 
valve implantation (TAVI) in the private healthcare system with the 
hypothetical scenario 1 (increased use of TAVI) and hypothetical sce-
nario 2 (decreased use of TAVI).
Figure 5 – Accumulated results of budgetary impact on the horizon 
of five years for the three scenarios analyzed.
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that this population should be prioritized with respect 
to the access to public and private services, including 
the right of access to healthcare.
With respect to patients with severe AS and without 
prospect of surgical treatment, TAVI – the scenario evalu-
ated in this study – is the only alternative therapy that 
can alter the natural course of this severe cardiovascular 
disease, due to the significant reduction of mortality 
compared to the conservative strategy, as was clearly 
demonstrated by the PARTNER trial.17 Thus, this therapy 
has been evaluated and incorporated in several countries. 
In Brazil, although the technique has been available 
since 2008, with registration by the National Health 
Surveillance Agency (Agência Nacional de Vigilância 
Sanitária – ANVISA) of the first valve prosthesis for 
transcatheter implantation, there is no provision of 
of mandatory coverage in the national health system, 
which results in the exclusion of significant portion of 
these elderly patients from the benefit of a scientifically 
appropriate treatment.
As demonstrated in this study, the ICER of TAVI 
ranges between R$ 49,770 and R$ 85.957/year of life 
saved, varying mainly due to the price of the prosthesis 
used. This value, however, is below the limit usually 
accepted as a criterion for incorporation, which is 
US$50,000.21 The budgetary impact of the procedure 
is considerable, mainly due to the price of the valve 
prosthesis. However, since 2011, when the List of Pro-
cedures of ANS for 2010 was updated and published 
through the Normative Resolution 256, it can be observed 
that there was a significant reduction in the price of 
this prosthesis, of approximately 40%, compared to the 
reference value used in this study, and this fact should 
substantially reduce the expected impact. In addition, 
the authors emphasize that currently there are three 
similar prostheses with ANVISA registration and one of 
them is manufactured in Brazil; this fact may become 
even more favorable to the ICER of TAVI.
The main limitations of the economic model de-
veloped are those customary for similar studies in this 
country, namely the lack of local epidemiological data, 
the difficulty of collecting the costs, as well as the 
difficulty of projecting the procedure use based on a 
expert panel. However, these limitations are inhe rent to 
any economic study conducted in Brazil and, conside-
ring that its function is to provide a decision basis that 
allows the modern manager to be prepared for future 
funding of the procedure; this study provides important 
information that should be considered in the process 
of adoption of the technology in question.
The Brazilian guidelines published by the Minis-
try of Health21 with recommendations for Technology 
Assessment in Health, do not define a threshold ICER 
eligible for incorporation, unlike European countries, 
Canada, and Australia. However, on May 21, 2012, 
the Secretary of Healthcare of the Ministry of Health 
published in the Official Gazette a decree (SAS De-
cree #458) with reference to the value of US$ 50,000 
as the upper limit of the ICER. Using this value as a 
reference, the TAVI procedure would be cost-effective 
for the Brazilian scenario, considering the limit of R$ 
100,000, at a current exchange rate of approximately 
US$ 1.00/R$ 2.00. Considering the value for the ICER 
found in this study, is it wise to emphasise that other 
technologies have been incorporated by the private 
healthcare system with similar cost increment, with the 
recent example of implantable cardiac defibrillators.
Finally, it should be noted that, due to the ab-
sence of mandatory coverage for TAVI, this situation 
has fostered a growing judicialization in this context, 
aiming at the implementation of the right to receive 
such treatment with culminated effects. Thus, through 
the courts, healthcare plan operators are being forced to 
bear these additional costs, and in a worst-case scenario 
from the financial perspective. Therefore, the value of 
the ICER calculated in this study actually overestimates 
the real budgetary impact of its incorporation in the 
realm of private healthcare, considering that resources 
are already effectively being allocated for this purpose.
CONCLUSIONS
Severe aortic stenosis is a disease that requires 
a substantial expenditure from the private healthcare 
system. The only treatment required in the sphere of 
the private healthcare system – balloon aortic val-
vuloplasty – does not alter the natural history of the 
disease. In contrast, patients treated with TAVI benefit 
from longer life expectancy, when compared to patients 
who undergo only conservative treatment. Furthermore, 
almost all casesusing TAVI, when compared to standard 
treatment, demonstrate greater effectiveness and incre-
mental cost, evidencing its robustness in the result of 
economic analysis.
Additionally, the budgetary impact analysis showed 
that the incorporation of the transcatheter aortic valve 
implantation in the List of Health Procedures and 
Events of the National Supplemental Health Agency 
(Agência Nacional de Saúde Suplementar), in the form 
as evaluated in this trial, would involve an estimated 
incremental budgetary impact over the next five years 
between R$ 70 million and R$ 121 million, consistent 
with other technologies already incorporated in the 
private healthcare system.
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